Biotest Aktiengesellschaft (BIO3) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biotest Aktiengesellschaft (BIO3) has a cash flow conversion efficiency ratio of -0.114x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-58.10 Million ≈ $-67.93 Million USD) by net assets (€509.60 Million ≈ $595.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biotest Aktiengesellschaft - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Biotest Aktiengesellschaft's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Biotest Aktiengesellschaft balance sheet liabilities for a breakdown of total debt and financial obligations.
Biotest Aktiengesellschaft Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biotest Aktiengesellschaft ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nichidenbo Corp
TW:3090
|
0.017x |
|
Seah Steel Corp
KO:003030
|
0.007x |
|
Gallant Precision Machining Co Ltd
TWO:5443
|
0.031x |
|
COMPASS PATHW SP.ADR
F:5Y6
|
N/A |
|
Mensch und Maschine Software SE
F:MUM
|
-0.016x |
|
Chapters Group AG
XETRA:CHG
|
0.040x |
|
NTG Nordic Transport Group A/S
CO:NTG
|
0.047x |
|
REGAL PARTNERS LTD.
F:OC7
|
N/A |
Annual Cash Flow Conversion Efficiency for Biotest Aktiengesellschaft (2002–2024)
The table below shows the annual cash flow conversion efficiency of Biotest Aktiengesellschaft from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see BIO3 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €530.70 Million ≈ $620.44 Million |
€60.90 Million ≈ $71.20 Million |
0.115x | +2220.40% |
| 2023-12-31 | €498.90 Million ≈ $583.27 Million |
€-2.70 Million ≈ $-3.16 Million |
-0.005x | +95.04% |
| 2022-12-31 | €371.10 Million ≈ $433.85 Million |
€-40.50 Million ≈ $-47.35 Million |
-0.109x | -222.46% |
| 2021-12-31 | €380.40 Million ≈ $444.73 Million |
€33.90 Million ≈ $39.63 Million |
0.089x | +335.65% |
| 2020-12-31 | €441.60 Million ≈ $516.28 Million |
€-16.70 Million ≈ $-19.52 Million |
-0.038x | +46.32% |
| 2019-12-31 | €476.90 Million ≈ $557.55 Million |
€-33.60 Million ≈ $-39.28 Million |
-0.070x | +30.22% |
| 2018-12-31 | €495.20 Million ≈ $578.94 Million |
€-50.00 Million ≈ $-58.46 Million |
-0.101x | -202.38% |
| 2017-12-31 | €347.80 Million ≈ $406.61 Million |
€34.30 Million ≈ $40.10 Million |
0.099x | -46.02% |
| 2016-12-31 | €360.70 Million ≈ $421.70 Million |
€65.90 Million ≈ $77.04 Million |
0.183x | +97.71% |
| 2015-12-31 | €412.30 Million ≈ $482.02 Million |
€38.10 Million ≈ $44.54 Million |
0.092x | +489.25% |
| 2014-12-31 | €480.20 Million ≈ $561.40 Million |
€-11.40 Million ≈ $-13.33 Million |
-0.024x | -51.90% |
| 2013-12-31 | €460.70 Million ≈ $538.61 Million |
€-7.20 Million ≈ $-8.42 Million |
-0.016x | -116.63% |
| 2012-12-31 | €369.43 Million ≈ $431.91 Million |
€34.73 Million ≈ $40.60 Million |
0.094x | -54.92% |
| 2011-12-31 | €346.67 Million ≈ $405.29 Million |
€72.28 Million ≈ $84.50 Million |
0.208x | -17.59% |
| 2010-12-31 | €307.61 Million ≈ $359.63 Million |
€77.83 Million ≈ $90.99 Million |
0.253x | +115.51% |
| 2009-12-31 | €269.86 Million ≈ $315.50 Million |
€31.68 Million ≈ $37.04 Million |
0.117x | -13.75% |
| 2008-12-31 | €253.37 Million ≈ $296.22 Million |
€34.49 Million ≈ $40.32 Million |
0.136x | -5.47% |
| 2007-12-31 | €225.76 Million ≈ $263.94 Million |
€32.51 Million ≈ $38.01 Million |
0.144x | -1.85% |
| 2006-12-31 | €179.31 Million ≈ $209.64 Million |
€26.31 Million ≈ $30.76 Million |
0.147x | -12.46% |
| 2005-12-31 | €168.97 Million ≈ $197.55 Million |
€28.32 Million ≈ $33.11 Million |
0.168x | -28.46% |
| 2004-12-31 | €107.97 Million ≈ $126.22 Million |
€25.29 Million ≈ $29.57 Million |
0.234x | +46.49% |
| 2003-12-31 | €103.29 Million ≈ $120.75 Million |
€16.52 Million ≈ $19.31 Million |
0.160x | +619.93% |
| 2002-12-31 | €110.79 Million ≈ $129.53 Million |
€2.46 Million ≈ $2.88 Million |
0.022x | -- |
About Biotest Aktiengesellschaft
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for… Read more